Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study

Development and Validation of the Lupus Impact Tracker: A Patient-Completed Tool for Clinical Practice to Assess and Monitor the Impact of Systemic Lupus Erythematosus

(2014) Meenakshi Jolly et al.   ARTHRITIS CARE & RESEARCH

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

(2013) Daniel J Wallace et al.   ANNALS OF THE RHEUMATIC DISEASES

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab

(2013) E. A. Rossi et al.   BLOOD

Cumulative Burden of Oral Corticosteroid Adverse Effects and the Economic Implications of Corticosteroid Use in Patients With Systemic Lupus Erythematosus

(2013) Manan Shah et al.   CLINICAL THERAPEUTICS

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

(2013) Daniel J. Wallace et al.   RHEUMATOLOGY

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006

(2013) V. Strand et al.   RHEUMATOLOGY

CD22 ligation inhibits downstream B cell receptor signaling and Ca2+flux upon activation

(2012) N. Sieger et al.   ARTHRITIS AND RHEUMATISM

CD22 and Autoimmune Disease

(2012) Thomas Dörner et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Disease-Specific Patient Reported Outcome Tools for Systemic Lupus Erythematosus

(2012) Meenakshi Jolly et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Mechanisms of B cell autoimmunity in SLE

(2011) Thomas Dörner et al.   ARTHRITIS RESEARCH & THERAPY

Treatment of systemic lupus erythematosus with epratuzumab

(2010) Pawel Traczewski et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Newer Biological Agents in Rheumatoid Arthritis

(2010) Vibeke Strand et al.   DRUGS

B cells as therapeutic targets in SLE

(2010) Iñaki Sanz et al.   Nature Reviews Rheumatology

Numerical scoring for the BILAG-2004 index

(2010) Chee-Seng Yee et al.   RHEUMATOLOGY

Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases

(2009) V Strand et al.   ANNALS OF THE RHEUMATIC DISEASES

Prednisone, Lupus Activity, and Permanent Organ Damage

(2009) M. THAMER et al.   JOURNAL OF RHEUMATOLOGY

Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial

(2009) Vibeke Strand et al.   ARTHRITIS RESEARCH & THERAPY